Yin and Yang: Complement activation and regulation in Alzheimer's disease

Progress in Neurobiology

Volumn 70, Issue 6, 2003, Pages 463-472

  Shen, Yong ^a,c   Meri, Seppo ^b  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF HELSINKI   (Finland)

^c ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTITHROMBIN III; BENZODIAZEPINE DERIVATIVE; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C5A RECEPTOR; CORDIOL; FUCAN; HEPARIN; HERBACEOUS AGENT; NAFAMSTAT MESILATE; PEXELIZUMAB; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROTEOGLYCAN; SERINE PROTEINASE INHIBITOR; SYRINGIN; TRYPSIN INHIBITOR; UNCLASSIFIED DRUG; VACCINE;

ALZHEIMER DISEASE; CELL DAMAGE; CLINICAL TRIAL; COGNITIVE DEFECT; COMPLEMENT ACTIVATION; CORRELATION ANALYSIS; HUMAN; IMMUNIZATION; MOLECULAR INTERACTION; NERVE DEGENERATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; VACCINATION;

EID: 0141991166     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2003.08.001     Document Type: Review

References (109)

1. Afagh A., Cummings B., Cribbs D., Cotman C.W., Tenner A.J. Localization and cell association of C1q in Alzheimer's disease brain. Exp. Neurol. 138:1996;22-32.
2. Almeda S., Rosenberg R.D., Bing D.H. The binding properties of human complement component C1q: interaction with mucopolysaccharides. J. Biol. Chem. 258:1983;785-791.
3. Ashall F., Goate A.M. Role of the beta-amyloid precursor protein in Alzheimer's disease. Trends Biochem. Sci. 19:1994;42-46.
4. Backssai B.J., Kajdasz S.T., Christie R.H., Carter C., Games D., Seubert P., Schenk D., Hyman B.T. Nat. Med. 7:2001;369-372.
5. Bard F., Cannon C., Barbour R., Burke R.-L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wodd K. Peripherally administered antibodies against amyloid beta peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:2000;916-919.
6. Bird T.D., Boehnke M., Anderson J., Lampe T.H., Schellenberg G., Larson E.B. The frequency of C4B variants of complement in familial and sporadic Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1(4):1987;251-255.
7. Blondin C., Fisher E., Boisson-Vidal C., Kazatchkine M.D., Jozefonvicz J. Inhibition of complement activation by natural sulfated polysaccharides (fucans) from brown seaweed. Mol. Immunol. 31:1994;247-253.
8. Botto M., Dell'Agnola C., Bygrave A.E., Thompson E.M., Cook H.T., Petry F., Loos M., Pandolfi P.P., Walport M.J. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet. 19(1):1998;56-59.
9. Boyett K.W., DiCarlo G., Jantzen P.T., Jackson J., O'Leary C., Wilcock D., Morgan D., Gordon M.N. Increased fibrillar beta-amyloid in response to human clq injections into hippocampus and cortex of APP + PS1 transgenic mice. Neurochem. Res. 28(1):2003;83-93.
10. Bradt B.M., Kolb W.P., Cooper N.R. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J. Exp. Med. 188(3):1998;431-438.
11. Brazil M.I., Chung H., Maxfield F.R. Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer's disease amyloid fibrils by microglia. J. Biol. Chem. 275(22):2000;16941-16947.
12. Breitner J.C., Gau B.A., Welsh K.A., Plassman B.L., McDonald W.M., Helms M.J., Anthony J.C. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology. 44:1994;227-232.
13. Brower M.S., Harpel P.C. Proteolytic cleavage and inactivation of alpha 2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase. J. Biol. Chem. 257:1982;9849-9854.
14. Carrell, R.W., Boswell, D.R., 1986. In: Barrett, A., Salvesen, G. (Eds.), Protease Inhibitors, pp. 403-420.
15. Carter P.E., Dunbar B., Fothergill J.E. Genomic and cDNA cloning of the human C1 inhibitor. Eur. J. Biochem. 173:1988;163-169.
16. Castro J.L., Broughton H.B., Russell M.G., Rathbone D., Watt A.P., Ball R.G., Chapman K.L., Patel S., Smith A.J., Marshall G.R., Matassa V.G. 5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor. J. Med. Chem. 40:1997;2491-2501.
17. Caughman G.B., Boackle R.J., Vesely J. A postulated mechanism for heparin's protentiation of C1 inhibitor function. Mol. Immunol. 19:1982;287-295.
18. Charreau B., Blondin C., Boisson-Vidal C., Soulillou J.P., Anegon I. Efficiency of fucans in protecting porcine endothelial cells against complement activation and lysis by human serum. Transplant Proc. 29(1-2):1997;889-890.
19. Davies A., Simmons D.L., Hale G., Harrison R.A., Tighe H., Lachmann P.J., Waldmann H. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J. Exp. Med. 170:1989;637-654.
20. DeMottos R.B., Bales K.R., Cummins D.L., Dodart J.-C., Paul S.M., Hotltzman D.M. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 98:2001;8850-8855.
21. de Zwaan C., Kleine A.H., Diris J.H., Glatz J.F., Wellens H.J., Strengers P.F., Tissing M., Hack C.E., van Dieijen-Visser M.P., Hermens W.T. Continuous 48. h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction Eur. Heart J. 23(21):2002;1670-1677.
22. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., DeLong C.A., Wu S., Wu X., Holtzman D.M., Paul S.M. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat. Neurosci. 5:2002;452-456.
23. Duarte M.E., Cardoso M.A., Noseda M.D., Cerezo A.S. Structural studies on fucoidans from the brown seaweed Sargassum stenophyllum. Carbohydr. Res. 333:2001;281-293.
24. Eikelenboom P., Stam F.C. Immunoglobulins and complement factors in senile plaques. Acta Neuropathol. (Berl.). 57:1982;239-242.
25. Eikelenboom P., Zhan S., van Gool W.et al. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol. Sci. 15:1994;447-450.
26. Fujita Y., Inoue I., Inagi R., Miyata T., Shinzato T., Sugiyama S., Miyama A., Maeda K. Inhibitory effect of FUT-175 on complement activation and its application for glomerulonephritis with hypocomplementemia. Nippo Jinzo Gakkai Shi. 35:1993;393-397.
27. Gandy S. Molecular basis for anti-amyloid therapy in the prevention and treatment of Alzheimer's disease. Neurobiol. Aging. 23(6):2002;1009-1016.
28. Gasque P., Ischenko A., Legoedec J., Mauger C., Schouft M.-T., Fontaine M. Expression of the complement classical pathway by human glioma in culture. J. Biol. Chem. 268:1993;25068-25074.
29. Gasque P., Chan P., Fontaine M., Ischenko A., Lamacz M., Gotze O., Morgan B.P. Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. J. Immunol. 155:1995;4882-4889.
30. Gerard N.P., Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature. 349:1991;614-617.
31. Glenner G.G., Wong C.W. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 122:1984;1131-1135.
32. Greenberg S.M., Bacskai B.J., Hyman B.T. Alzheimer disease's double-edged vaccine. Nat. Med. 9(4):2003;389-397.
33. Griffin W.S., Sheng J.G., Roberts G.W., Mrak R.E. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J. Neuropathol. Exp. Neurol. 54:1995;276-281.
34. Haga S., Ikeda K., Sato M., Ishii T. Synthetic Alzheimer amyloid beta/A4 peptides enhance production of complement C3 component by cultured microglial cells. Brain Res. 601:1993;88-94.
35. Hock C., Konietzko U., Papassotiropoulos A., Wollmer A., Streffer J., von Rotz R.C., Davey G., Moritz E., Nitsch R.M. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat. Med. 8(11):2002;1270-1275.
36. Ishii, T., Haga, S., Kametani, F., 1988. Presence of immunoglobulins and complements in the amyloid plaques in the brain of patients with Alzheimer's disease. In: Pouplard-Barthelaix, A., Emile, J., Christen, Y. (Eds.), Immunology and Alzheimer's Disease, vol. 17. Springer-Verlag, Berlin, pp. 17-29.
37. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chlshti M.A., Horne P., hestlin D., French J. Aβ immunization reduces behavioral impairment and plaques in a mode of Alzheimer disease. Nature. 408:2000;979-982.
38. Jiang H., Burdick D., Glabe C.G., Cotman C.W., Tenner A.J. β-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J. Immunol. 152:1994;5050-5059.
39. Johnson S., Lampert-Etchells M., Pasinetti G.M., Rozovsky I., Finch C.E. Complement mRNA in the mammalian brain: responses to Alzheimer's disease and experimental brain lesioning. Neurobiol. Aging. 13:1992;641-648.
40. Kapil A., Moza N. Anticomplementary activity of boswellic acids - an inhibitor of C3-convertase of the classical complement pathway. Int. J. Immunopharmacol. 14:1992;1139-1143.
41. Kapil A., Sharma S. Immunopotentiating compounds from Tinospora cordifolia. J. Ethnopharmacol. 58:1997;89-95.
42. Kirschfink M. Targeting complement in therapy. Immunol. Rev. 180:2001;177-189.
43. Kirschfink M., Mollnes T.E. C1-inhibitor: an anti-inflammatory reagent with therapeutic potential. Expert Opin. Pharmacother. 2:2001;1073-1083.
44. Kirschfink M., Blasé L., Engelmann S., Schwartz-Albiez R. Secreted chondroitin sulfate proteoglycan of human B cell lines binds to the complement protein C1q and inhibits complex formation of C1. J. Immunol. 158:1997;1324-1331.
45. Klegeris A., Schwab C., Bissonnette C.J., McGeer P.L. Induction of complement C9 messenger RNAs in human neuronal cells by inflammtory stimuli: relevance to neurodegenerative disorders. Exp. Gerontol. 36(7):2001;1179-1188.
46. Kooyman D.L., Byrne G.W., McClellan S., Nielsen D., Tone M., Waldmann H., Coffman T.M., McCurry K.R., Platt J.L., Logan J.S. In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science. 269:1995;89-92.
47. Kramer J., Rosen F.S., Colten H.R., Rajczy K., Strunk R.C. Transinhibition of C1 inhibitor synthesis in type I hereditary angioneurotic edema. J. Clin. Invest. 91(3):1993;1258-1262.
48. Law S.K., Fearon D.T., Levine R.P. Action of the C3b-inactivator on cell-bound C3B. J. Immunol. 122:2003;759-764.
49. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 82:1985;4245-4249.
50. Matsuoka Y., Picciano M., Malester B., LaFrancois J., Zehr C., Daeschner J.M., Olschowka J.A., Fonseca M.I., O'Banion M.K., Tenner A.J., Lemere C.A., Duff K. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol. 158(4):2001;1345-1354.
51. McGeer P.L., McGeer E. Is there a future for vaccination as a treatment for Alzheimer's disease? Neurobiol. Aging. 24(3):2003;391-395.
52. McGeer P.L., Akiyama H., Itagaki S., McGeer E.G. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci. Lett. 107:1989;341-346.
53. McGeer P.L., Walker D.G., Akiyama H., Kawamata A.L., Guan A.L., Parker C.J., Okada N., McGeer E.G. Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer's brain. Brain Res. 544:1991;315-319.
54. McGeer P.L., Schuler M., McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 47:1996;425-432.
55. McLaurin J., Cecal R., Kierstead M.E., Tian X., Phinney A.L., Manea M., French J.E., Lambermon M.H., Darabie A.A., Brown M.E., Janus C., Chishti M.A., Horne P., Westaway D., Fraser P.E., Mount H.T., Przybylski M., George-Hyslop P.S. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 8(11):2002;1263-1269.
56. Meri S., Morgan B.P., Davies A., Danials R.H., Olavesen M.G., Waldmann H., Lachmann P.J. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology. 72:1990;1-9.
57. Meri S., Waldmann H., Lachmann P.J. Distribution of protectin (CD59) a complement membrane attack inhibitor, in normal human tissues. Lab. Invest. 65:1991;532-537.
58. Morgan B.P. Complement regulatory molecules: application to therapy and transplantation. Immunol. Today. 16(6):1995;257-259.
59. Morgan D., Diamond D.M., Gottschali P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G.W. A peptide vaccination prevents memory deficits in an animal model of Alzheimer disease. Nature. 408:2000;982-985.
60. Mukherjee P., Pasinetti G.M. Complement anaphylatoxin C5a neuroprotects through mitogen-activated protein kinase-dependent inhibition of caspase 3. J. Neurochem. 77(1):2001;43-49.
61. Muller-Eberhard H.J. Molecular organization and function of the complement system. Annu. Rev. Biochem. 57:1988;321-347.
62. Mulligan M.S., Yeh C.G., Rudolph A.R., Ward P.A. Protective effects of soluble CR1 in complement and neutrophil-mediated tissue injury. J. Immunol. 148:1992;479-485.
63. Nerl C., Mayeux R., O'Neill G.J. HLA-linked complement markers in Alzheimer's and Parkinson's disease: C4 variant (C4B2) a possible marker for senile dementia of the Alzheimer type. Neurology. 34(3):1984;310-314.
64. Nicoll J.A.R., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9:2003;448-452.
65. O'Barr S.A., Caguioa J., Gruol D., Perkins G., Ember J.A., Hugli T., Cooper N.R. Neuronal expression of a functional receptor for the C5a complement activation fragment. J. Immunol. 166(6):2001;4154-4162.
66. Oceio-Vinyals J.G., Leyva-Cobian F., Fernandez-Luna J.L. A mutation unique in serine protease inhibitors (serpins) identified in a family with type II hereditary angioneurotic edema. Mol. Med. 1:1995;700-705.
67. Osaka H., Mukherjee P., Aisen P.S., Pasinetti G.M. Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J. Cell Biochem. 73(3):1999;303-311.
68. Powell M.B., Marchbank K.J., Rushmere N.K., van den Berg C.W., Morgan B.P. Molecular cloning, chromosomal localization, expression, and functional characterization of the mouse analogue of human CD59. J. Immunol. 158(4):1997;1692-1702.
69. Price D.L., Sisodia S.S. Toxicity of synthetic Aβ peptide and modeling of Alzheimer's disease. Ann. Neurosci. 13:1998;623-625.
70. Reid K.B., Porter R.R. The proteolytic activation systems of complement. Annu. Rev. Biochem. 50:1981;433-464.
71. Rich J.B., Rasmusson D.X., Folstein M.F., Carson K.A., Kawas C., Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology. 45:1995;51-55.
72. Rocha H.A., Franco C.R., Trindade E.S., Caryalho L.C., Veiga S.S., Leite E.L., Dietrich C.P., Nader H.B. A fucan from the brown seaweed Spatoglossum schroederi inhibits Chinese hamster ovary cell adhesion to several extracellular matrix proteins. Braz. J. Med. Biol. Res. 34:2001;621-626.
73. Rogers, J., O'Barr, S., 1997. Inflammatory mediators in Alzheimer's disease. In: Tanzi, R., Wasco, W. (Eds.), Molecular Mechanisms of Dementia. Human Press, Totowa, NJ, pp. 177-198.
74. Rogers J., Cooper N., Webster S., Schultz J., McGeer P., Styren S.D., Civin W.H., Brachova L., Bradt B., Ward P., Lieberburg I. Complement activation by β-amyloid in Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 89:1992;10016-10020.
75. Rogers J., Kirby L., Hempelman S., Berry D.L., McGeer P.L., Kaszniak A.W., Zalinski J., Cofield M., Mansukhani L., Wilson P., Kogan F. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 43:1993;1609-1611.
76. Rollins S.A., Zhao J., Ninomiya H., Sims P.J. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J. Immunol. 146(7):1991;2345-2351.
77. Sarvari M., Vago I.I., Weber C.S., Nagy J., Gal P., Mak M., Kosa J.P., Zavodszky P., Pazmany T. Inhibition of C1q-beta-amyloid binding protects hippocampal cells against complement mediated toxicity. J. Neuroimmunol. 137(1-2):2003;12-18.
78. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K. Immunization with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature. 40:1999;173-177.
79. Selkoe D.J., Yamazaki T., Citron M., Podlisny M.B., Koo E.H., Teplow D.B., Haass C. The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Ann. N. Y. Acad. Sci. 777:1996;57-64.
80. Shen Y., Halperin J.A., Lee C.-M. Complement-mediated neurotoxicity is regulated by homologous restriction. Brain Res. 671:1995;282-292.
81. Shen Y., Li R., McGeer E., McGeer P. Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer's brain. Brain Res. 769:1997;391-395.
82. Shen Y., Sullivan T., Meri S., Shiosaki K., Lin C.W. Induced expression of neuronal membrane attack complex (MAC) and cell death by beta-amyloid peptide. Brain Res. 796:1998;187-197.
83. Shen Y., Lue L., Yang L., Roher A., Kuo Y., Stromeyer R., Goux W.J., Lee V., Johnson G.V., Webster S.D., Cooper N.R., Bradt B., Rogers J. Complement activation by neurofibrillary tangles in Alzheimer's disease. Neurosci. Lett. 305(3):2001;165-168.
84. Sigurdsson E.M., Wisniewski T., Frangione B. A safer vaccine for Alzheimer's disease? Neurobiol. Aging. 23(6):2002;1001-1008.
85. Singhrao S.K., Neal J.W., Morgan B.P., Gasque P. Increased complement biosynthesis by microglia and complement activation on neurons in Huntigton's disease. Exp. Neurol. 159:1999;362-376.
86. Singhrao S.K., Neal J.W., Rushmere N.K., Morgan B.P., Gasque P. Spontaenous classical pathway activation and deficiency of membrane regulators render human neurons suseptible to complement lysis. Am. J. Pathol. 157:2000;905-918.
87. Sisodia S.S., Gallagher M. A role for the beta-amyloid precursor protein in memory? Proc. Natl. Acad. Sci. U.S.A. 95:1998;12074-12076.
88. Storch M.K., Piddlesden S., Haltia M., Iivanainen M., Morgan P., Lassmann H. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann. Neurol. 43(4):1998;465-471.
89. Van Beek J., Bernaudin M., Petit E., Gasque P., Nouvelot A., MacKenzie E.T., Fontaine M. Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse. Exp. Neurol. 161:2000;373-382.
90. Vedeler C.A., Matre R. Peripheral nerve CR1 express in situ cofactor activity for degradation of C3b. J. Neuroimmunol. 26:1990;51-56.
91. Vedeler C.A., Gihus N.E., Matre R. Erythrocyte C3b/C4b receptors (CR1) in patients with myasthenia gravis. Autoimmunity. 6:1990;235-236.
92. Veerhuis R., Janssen I., Hoozemans J.J., De Groot C.J., Hack C.E., Eikelenboom P. Complement C1 inhibitor expression in Alzheimer's disease. Acta Neuropathol. (Berl.). 96:1998;287-296.
93. Velazquez P., Cribbs D.H., Poulos T.L., Tenner A.J. Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis. Nat. Med. 3(1):1997;77-79.
94. Walker D.G., McGeer P.L. Complement gene expression in human brain: comparison between normal and Alzheimer disease cases. Mol. Brain Res. 14:1992;109-116.
95. Walker D.G., Yasuhara O., Patston P.A., McGeer E.G., McGeer P.L. Complement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer disease. Brain Res. 675:1995;75-82.
96. Webster S., O'Barr S., Rogers J. Enhanced aggregation and structure of amyloid peptide after coincubation with C1q. J. Neurosci. Res. 39:1994;448-456.
97. Webster S., Glabe C., Rogers J. Multivalent binding of complement protein C1q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation. Biochem. Biophys. Res. Commun. 217:1995;869-875.
98. Webster S., Lue L.F., Brachova L., Tenner A.J., McGeer P.L., Terai K., Walker D.G., Bradt B., Cooper N.R., Rogers J. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol. Aging. 18:1997;415-421.
99. Webster S.D., Galvan M.D., Ferran E., Garzon-Rodriguez W., Glabe C.G., Tenner A.J. Antibody-mediated phagocytosis of the amyloid beta-peptide in microglia is differentially modulated by C1q. J. Immunol. 166(12):2001; 7496-7503.
100. Wegger S., Erikson J.L., Das P., Sagi S.A., Wang R., Pietrzik C.U., Findlay K.A., Smith T.E., Murphy M.P., Bulter T., Kang D.E., Marquez-Sterling N., Gold T.E., Koo E.A. A subset of NSAIDs lower amyloidogenic Abeta 42 independently of cyclooxygenase activity. Nature. 414:2001;212-216.
101. Weiler J.M., Yurt R.W., Fearon D.T., Austen K.F. Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin. J. Exp. Med. 147:1978;409-421.
102. Weiner H.L., Selkoe D.J. Inflammation and therapeutic vaccination in CNS diseases. Nature. 420(6917):2002;879-884.
103. Weisman H.F., Bartow T., Leppo M.K. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science. 249:1990;146-151.
104. Whiss P.A. Pexelizumab Alexion. Curr. Opin. Investig. Drugs. 3(6):2002;870-877.
105. Wong A.K., Finch A.M., Pierens G.K., Craik D.J., Taylor S.M., Fairlie D.P. Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derive from the C terminus of the human plasma protein C5a. J. Med. Chem. 41:1998;3417-3425.
106. Wyss-Coray T., Yan F., Lin A.H., Lambris J.D., Alexander J.J., Quigg R.J., Masliah E. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl. Acad. Sci. U.S.A. 99(16):2002;10837-10842.
107. Yang L.B., Li R., Meri S., Rogers J., Shen Y. Deficiency of complement defense protein, CD59, may contribute to neurodegeneration of Alzheimer's brains. J. Neurosci. 20(20):2000;1600-1618.
108. Zhan S.S., Veerhuis R., Janssen I., Kamphorst W., Eikelenboom P. Immunohistochemical distribution of the inhibitors of the terminal complement complex in Alzheimer's disease. Neurodegeneration. 3:1994;111-117.
109. Zhang X., Boyar W., Galakatos N., Gonnella N.C. Solution structure of a unique C5a semi-synthetic antagonist: implications in receptor binding. Protein Sci. 6:1997;65-72.